Related Experiment Video
Updated: Jul 2, 2026

Revealing the Ferroptotic Phenotype of Medulloblastoma
Published on: March 15, 2024
Divergent roles of SPOP and CHD1 in ACSL4 regulation reveal context-dependent vulnerabilities for targeting
Feiyu Chen1, Qidong Li1, Qianlin Gu1
1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Abstract:
Genetic heterogeneity contributes to the variable therapeutic responses in cancers. Frequent SPOP mutations and recurrent CHD1 deletions define distinct molecular subtypes of prostate cancer (PCa) with differential responses to anti-androgen therapy. Ferroptosis, an iron-dependent cell death mechanism driven by lipid peroxidation, has emerged as a promising anticancer strategy. Here, we identify SPOP mutations and CHD1 deletion as key genetic determinants of ferroptosis susceptibility in PCa. Using genetically engineered human and murine models, we show that SPOP mutations enhance, whereas CHD1 deletion impairs, the efficacy of ferroptosis inducers targeting GPX4. Mechanistically, SPOP and CHD1 exert opposing effects on ferroptosis by antagonistically regulating the MYC-ACSL4 axis. Furthermore, we demonstrate that targeting cholesterol metabolism with cholesterol-lowering agents restores ACSL4 expression and re-sensitizes SPOP/CHD1 co-deficient tumors to ferroptosis-inducing therapy. Our findings establish SPOP/CHD1 as upstream genetic regulators of ferroptosis and provide biomarker-driven combinatorial strategies to enhance ferroptosis-based therapy in men with advanced PCa.
Insights
Genetic mutations in SPOP and CHD1 influence prostate cancer
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Prostate cancer (PCa) exhibits genetic heterogeneity impacting treatment outcomes.
- SPOP mutations and CHD1 deletions define PCa subtypes with varied responses to anti-androgen therapy.
- Ferroptosis, a cell death pathway, presents a novel anticancer strategy.
Purpose of the Study:
- To investigate the role of SPOP mutations and CHD1 deletions in ferroptosis susceptibility in prostate cancer.
- To elucidate the molecular mechanisms by which SPOP and CHD1 regulate ferroptosis.
- To explore therapeutic strategies combining ferroptosis inducers with agents targeting cholesterol metabolism.
Main Methods:
- Utilized genetically engineered human and murine models of prostate cancer.
- Investigated the effects of SPOP mutations and CHD1 deletion on ferroptosis inducer efficacy (targeting GPX4).
- Analyzed the regulation of the MYC-ACSL4 axis and its role in ferroptosis.
Main Results:
- SPOP mutations increase, while CHD1 deletions decrease, ferroptosis susceptibility in PCa.
- SPOP and CHD1 antagonistically regulate the MYC-ACSL4 axis, controlling ferroptosis.
- Targeting cholesterol metabolism with cholesterol-lowering agents re-sensitized SPOP/CHD1 co-deficient tumors to ferroptosis inducers by restoring ACSL4 expression.
Conclusions:
- SPOP and CHD1 act as key upstream genetic regulators of ferroptosis in prostate cancer.
- Combinatorial strategies targeting cholesterol metabolism and ferroptosis show promise for advanced PCa.
- Biomarker-driven approaches using SPOP/CHD1 status can guide ferroptosis-based therapy selection.
Related Concept Videos
Hedgehog Signaling Pathway
Spreading of Chromatin Modifications
Writers
The writer is an enzyme that can...
The Ratio of X Chromosome to Autosomes
Normal male Drosophila has a ratio of one X chromosome to two sets of autosomes. In contrast, normal female Drosophila...
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Regulation of Nuclear Protein Sorting
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.